Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
PLoS One ; 7(5): e37379, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22662150

RESUMO

UNLABELLED: Adjuvant chemotherapy decisions in breast cancer are increasingly based on the pathologist's assessment of tumor proliferation. The Swiss Working Group of Gyneco- and Breast Pathologists has surveyed inter- and intraobserver consistency of Ki-67-based proliferative fraction in breast carcinomas. METHODS: Five pathologists evaluated MIB-1-labeling index (LI) in ten breast carcinomas (G1, G2, G3) by counting and eyeballing. In the same way, 15 pathologists all over Switzerland then assessed MIB-1-LI on three G2 carcinomas, in self-selected or pre-defined areas of the tumors, comparing centrally immunostained slides with slides immunostained in the different laboratoires. To study intra-observer variability, the same tumors were re-examined 4 months later. RESULTS: The Kappa values for the first series of ten carcinomas of various degrees of differentiation showed good to very good agreement for MIB-1-LI (Kappa 0.56-0.72). However, we found very high inter-observer variabilities (Kappa 0.04-0.14) in the read-outs of the G2 carcinomas. It was not possible to explain the inconsistencies exclusively by any of the following factors: (i) pathologists' divergent definitions of what counts as a positive nucleus (ii) the mode of assessment (counting vs. eyeballing), (iii) immunostaining technique, and (iv) the selection of the tumor area in which to count. Despite intensive confrontation of all participating pathologists with the problem, inter-observer agreement did not improve when the same slides were re-examined 4 months later (Kappa 0.01-0.04) and intra-observer agreement was likewise poor (Kappa 0.00-0.35). CONCLUSION: Assessment of mid-range Ki-67-LI suffers from high inter- and intra-observer variability. Oncologists should be aware of this caveat when using Ki-67-LI as a basis for treatment decisions in moderately differentiated breast carcinomas.


Assuntos
Neoplasias da Mama/diagnóstico , Antígeno Ki-67/metabolismo , Neoplasias da Mama/tratamento farmacológico , Neoplasias da Mama/patologia , Quimioterapia Adjuvante , Feminino , Humanos , Imuno-Histoquímica , Gradação de Tumores , Variações Dependentes do Observador
2.
Rev Med Suisse ; 3(119): 1743-6, 2007 Jul 18.
Artigo em Francês | MEDLINE | ID: mdl-17727095

RESUMO

In pediatric pathology, diagnosis explores major aspects of childhood disorders ranging from malformative syndromes to neoplasm's and forensic pathology. For this mental gymnastics, knowledge of the different morphological and physiological process of development and adaptation are essential. Furthermore, new adjuvant technology ensure a more precise diagnosis by the pediatric pathologist. A review of some particular situations in child are illustrated below.


Assuntos
Patologia Clínica , Pediatria , Criança , Humanos , Equipe de Assistência ao Paciente
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...